Stockreport

Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100%Cirmtuzumab has been very well tolera [Read more]